Regulatory Fate of Cancer Indications in the European Union After Accelerated Approval in the US

被引：1
|
作者：
Petersen, Tonny Studsgaard [1 ,2 ]
Karstoft, Kristian [1 ,2 ]
Sorup, Freja Karuna Hemmingsen [1 ,2 ]
Lund, Marie [1 ,2 ,3 ]
Cramer, Allan [1 ]
机构：
[1] Copenhagen Univ Hosp Bispebjerg & Frederiksberg, Dept Clin Pharmacol, Bispebjerg Bakke 23,2400 Kbh NV, DK-2400 Copenhagen, Denmark
[2] Univ Copenhagen, Dept Clin Med, Copenhagen, Denmark
[3] Statens Serum Inst, Dept Epidemiol Res, Copenhagen, Denmark
来源：
JAMA ONCOLOGY | 2025年 / 11卷 / 01期
关键词：
D O I：
10.1001/jamaoncol.2024.5145
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：70 / 71
页数：2
相关论文
共 50 条
  • [31] Cancer Drug Development and the Evolving Regulatory Framework for Companion Diagnostics in the European Union
    Pignatti, Francesco
    Ehmann, Falk
    Hemmings, Robert
    Jonsson, Bertil
    Nuebling, Micha
    Papaluca-Amati, Marisa
    Posch, Martin
    Rasi, Guido
    CLINICAL CANCER RESEARCH, 2014, 20 (06) : 1458 - 1468
  • [32] Gleevec™ for the treatment of chronic myelogenous leukemia:: US food and drug administration regulatory mechanisms, accelerated approval, and orphan drug status
    Cohen, MH
    Moses, ML
    Pazdur, R
    ONCOLOGIST, 2002, 7 (05): : 390 - 392
  • [33] A review of patient-reported outcomes used for regulatory approval of oncology medicinal products in the European Union between 2017 and 2020
    Teixeira, Maria Manuel
    Borges, Fabio Cardoso
    Ferreira, Paula Sousa
    Rocha, Joao
    Sepodes, Bruno
    Torre, Carla
    FRONTIERS IN MEDICINE, 2022, 9
  • [34] Letter to the Editor Regarding: " Regulatory Framework for Implantable Neurostimulation Devices: Comparison of Systems in the US and European Union" "
    McLean, Aaron Lawson
    Nemir, Jakob
    NEUROMODULATION, 2024, 27 (03): : 1102 - 1103
  • [35] Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia
    Hwang, Thomas J.
    Kesselheim, Aaron S.
    Tibau, Ariadna
    Lee, ChangWon C.
    Vokinger, Kerstin N.
    JCO ONCOLOGY PRACTICE, 2022, 18 (09) : 676 - E1532
  • [36] Regulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: retrospective obser-vational study
    Gyawali, Bishal
    Rome, Benjamin N.
    Kesselheim, Aaron S.
    BMJ-BRITISH MEDICAL JOURNAL, 2021, 374
  • [37] Timing of Pediatric Drug Approval and Clinical Evidence Submitted to Regulatory Authorities: International Comparison Among Japan, the United States, and the European Union
    Hirota, Saeko
    Yamaguchi, Takuhiro
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 108 (05) : 985 - 994
  • [38] Post-approval quality-related regulatory actions for biopharmaceuticals approved in the European Union and the United States between 1995 and 2019
    Alsamil, Ali M.
    Gardarsdottir, Helga
    Leufkens, Hubert G.
    Egberts, Toine C.
    Giezen, Thijs J.
    DRUG DISCOVERY TODAY, 2023, 28 (10)
  • [39] A decade of marketing approval of gene and cell based therapies in the United States, European Union, and Japan: A regulatory decision-making evaluation
    Coppens, Delphi G. M.
    de Wilde, Sofieke
    Guchelaar, Henk J.
    De Bruin, Marie L.
    Leufkens, Hubert G. M.
    Meij, Pauline
    Hoekman, Jarno
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 517 - 517
  • [40] Association of accelerated approval (AA) status with National Comprehensive Cancer Network (NCCN) guideline recommendation for cancer drug indications: A cross-sectional study
    Cliff, Edward Robert Scheffer
    Rome, Rachel S.
    Kesselheim, Aaron S.
    Rome, Benjamin N.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345